遗传性转甲状腺素蛋白淀粉样变性累及中枢神经系统
综述指出遗传性转甲状腺素蛋白淀粉样变性(ATTRv)的中枢神经系统受累正成为重要临床问题。软脑膜淀粉样沉积在早期即可见,V30M突变者周围神经病症状出现至少14年后常见中枢症状,非V30M突变者多为眼软脑膜淀粉样变性重症表型且系统受累轻。病理见软脑膜严重沉积及脑淀粉样血管病,沉积多来自脑脊液产生的TTR,对现有提升血浆TTR稳定性或减少其生成的疗法似不敏感。
要点
- ATTRv淀粉样变性软脑膜沉积在疾病早期即可出现,应警惕中枢受累。
- V30M突变者中枢症状多在周围神经病症状出现至少14年后作为晚期并发症出现。
- 非V30M突变者可表现为眼软脑膜淀粉样变性重症表型,系统受累轻,涉及至少14种突变。
核心结论
- 中枢神经系统受累在ATTRv淀粉样变性中并不少见,且现有针对血浆TTR的疗法对中枢沉积似不敏感,未来将成为患者管理的重要问题。
研究设计与样本
- 本文为综述,汇总近期关于ATTRv淀粉样变性中枢神经系统受累的研究与病例报告。
主要发现
- 软脑膜淀粉样沉积在ATTRv淀粉样变性早期即可见且较频繁。
- V30M突变患者在周围神经病症状出现至少14年后,中枢症状作为常见晚期并发症出现。
- 非V30M突变者多为眼软脑膜淀粉样变性重症表型,系统受累轻,涉及至少14种突变、见于全球罕见家系。
- 中枢症状包括短暂局灶性神经发作、出血性和缺血性卒中、认知下降及颅神经功能障碍。
- 病理见软脑膜严重淀粉样沉积及软脑膜和穿通血管的脑淀粉样血管病,沉积多由脑脊液产生的TTR形成。
临床怎么用
- 对ATTRv淀粉样变性患者应关注中枢神经系统症状,尤其在V30M突变者周围神经病症状出现至少14年后。
- 非V30M突变者出现眼或中枢功能障碍时需考虑眼软脑膜淀粉样变性,即使系统受累轻。
- 现有针对血浆TTR的疗法可能不能预防中枢沉积,需关注中枢受累的管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hereditary transthyretin amyloidosis (ATTRv amyloidosis) is predominantly a disease of the peripheral nerves, heart, kidney, and eye. CNS involvement has been a marginal issue in research and the clinical setting until recently. Growing evidence shows that leptomeningeal amyloid accumulation is frequent and present from early stages of ATTRv amyloidosis. Several recent studies show CNS symptoms arise as a common late complication in patients with the V30M mutation after at least 14 years of symptomatic peripheral nerve disease. Conversely, in non-V30M patients, there are several descriptions, mostly case reports, of patients presenting with severe phenotypes of ocular and CNS dysfunction (oculoleptomeningeal amyloidosis), with little systemic involvement. This phenotype is found in rare families worldwide, associated with at least 14 mutations. In both patients with late and early onset CNS dysfunction, symptoms include transient focal neurologic episodes, hemorrhagic and ischemic stroke, cognitive decline, and cranial nerve dysfunction. Pathologically, there is severe amyloid deposition in the leptomeninges and cerebral amyloid angiopathy of leptomeningeal and penetrating vessels. These amyloid aggregates are formed mostly by CSF-produced transthyretin (TTR) and seem resistant to the available ATTRv therapies that increase the stability or reduce the production of plasma TTR. This indicates that CNS involvement will become a meaningful issue in patient management in upcoming years.
引用
- Sousa L, Coelho T, Taipa R, et al. CNS Involvement in Hereditary Transthyretin Amyloidosis. Neurology. 2021. PMID: 34663645. doi:10.1212/WNL.0000000000012965
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。